Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Las Vegas Sands Corp. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Las Vegas Sands Corp. trades at $36.89 (market cap $23.98B). The key difference: Las Vegas Sands Corp. is far larger — about 2.7× Kymera Therapeutics Inc. Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Las Vegas Sands Corp. for 73 Days on average.
| KYMR | LVS | |
|---|---|---|
Market Cap | $8.88B | $23.98B |
Volume | 1,028,790 | 5,962,073 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $69.49 |
52-Week Low | $55.80 | $35.81 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $8.27B | $35.86B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LVS trades at $37.04, up 2.46% today, amid a bearish technical signal. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $58.89 price target, indicating significant upside potential. Recent news highlights Sands China's community initiatives and operational milestones, reinforcing its market presence.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and market volatility. Investment opportunity lies in the valuation discount relative to growth prospects, though investors should monitor earnings consistency and macroeconomic factors affecting the gaming and hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
